Science and Research

Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma-ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel approach for intrathoracic drug delivery. The aim of this study was to investigate cisplatin penetration characteristics and to evaluate procedural parameters influencing drug penetration, including temperature, drug concentration and pleural barrier function, in an ex vivo model. In addition, PITAC was compared with hyperthermic intrathoracic chemotherapy (HITOC), a treatment modality applied in selected specialized centers as part of multimodal treatment concepts for MPM. METHODS: We investigated the penetration depth and intensity of aerosolized cisplatin generated using a high-pressure nebulizer in an ex vivo setting. Potential influencing factors, including temperature, cisplatin concentration and barrier function of the pleura, were gradually modified, as we sought to evaluate optimal procedural conditions. Finally, PITAC was compared with a previously standardized HITOC approach. RESULTS: A temperature of 42

  • Flothmann, K.
  • Zinne, N.
  • Braubach, P.
  • Meininger, A.
  • Becker, I.
  • Ernst, N.
  • Ruhparwar, A.
  • Merhej, H.
  • Zardo, P.

Keywords

  • Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
  • hyperthermic intrathoracic chemotherapy (HITOC)
  • mesothelioma
  • pressurized intrathoracic aerosol chemotherapy
Publication details
DOI: 10.21037/jtd-2026-1-0258
Journal: J Thorac Dis
Pages: 516 
Number: 5
Work Type: Original
Location: BREATH
Disease Area: LC
Partner / Member: MHH
Access-Number: 42306705
See publication on PubMed


chevron-down